🏢 Companies — Corporate Intelligence
A comprehensive corporate intelligence platform covering the peptide (peptide) industry, featuring in-depth analysis of leading players, CDMO capacity assessments, startup funding dynamics, and global supply chain analysis.
📋 Corporate Section Navigation
| Section |
Core Content |
Coverage |
Update Frequency |
| Top Player Deep Dive |
Financials, technology & competitive analysis of top 10 players |
WuXi AppTec, Sinomartek, Sainuo Biotech, etc. |
Semi-annual |
| CDMO Capacity Landscape |
Capacity comparison, quality certifications, facility distribution |
Global major peptide CDMOs |
Annual |
| Startup Funding |
Funding rounds, amounts, investors |
China + Global Biotech |
Quarterly |
| Supply Chain Analysis |
Raw materials, equipment, manufacturing hubs, risks |
Global peptide value chain |
Annual |
🏆 Corporate Tier Overview (Peptide Revenue, Capabilities & Valuation)
| Tier |
Representative Companies |
2024 Peptide Revenue (¥B) |
Core Capability |
Valuation/Market Cap (¥B) |
GMP Certification |
Competitive Strength |
| T1 Global Leader |
WuXi AppTec (TIDES) |
~45 |
Full-chain CDMO + Platform Technology |
~2,000 |
FDA, EU, NMPA, PMDA |
⭐⭐⭐⭐⭐ |
| T1 International Leader |
Bachem (Switzerland) |
~28 (CHF 3.5B) |
Heritage + EU/US certification |
~300 (CHF) |
FDA, EU |
⭐⭐⭐⭐⭐ |
| T2 Specialist CDMO |
Sinomartek |
~22 |
GMP + GLP-1 API |
~150 |
NMPA, FDA |
⭐⭐⭐⭐ |
| T2 Specialist CDMO |
Sainuo Biotech |
~12 |
Molecular building blocks + custom |
~80 |
NMPA |
⭐⭐⭐⭐ |
| T2 Specialist CDMO |
Asymchem |
~15 |
GMP + Technology platform |
~400 |
NMPA |
⭐⭐⭐⭐ |
| T3 Niche Players |
Hybio |
~10 |
API export + generics |
~60 |
NMPA, FDA |
⭐⭐⭐ |
| T3 Niche Players |
Sunsom |
~5 |
Peptide generics |
~25 |
NMPA |
⭐⭐⭐ |
| T3 Niche Players |
Aurisco |
~4 |
Specialty API export |
~30 |
NMPA |
⭐⭐⭐ |
| T3 Niche Players |
Jiuzhou Pharma |
~3 |
Generic API |
~200 |
NMPA |
⭐⭐⭐ |
| T1 Innovative Drug |
Innovent Biologics |
~8 (GLP-1) |
Drug R&D + GLP-1 pipeline |
~600 |
NMPA |
⭐⭐⭐⭐ |
| T1 Innovative Drug |
Hengrui Pharma |
~7 (peptide pipeline) |
Full-chain drug R&D |
~3,000 |
NMPA, FDA |
⭐⭐⭐⭐ |
| International Specialist CDMO |
PolyPeptide (Belgium) |
~18 (€2.3B) |
EU/US GMP + injectables |
~50 (€) |
FDA, EU |
⭐⭐⭐⭐ |
2024–2025 Corporate Landscape: Key Characteristics
- Increasing market concentration: WuXi AppTec's peptide CDMO revenue exceeded ¥40B in 2024, with China CDMO market share rising from 18% to 32%
- GLP-1 dividend: GLP-1 API suppliers like Sinomartek saw 2024 revenue growth exceeding 100%, with Sinomartek's GLP-1 API revenue at ~¥18B
- Capacity arms race: Major CDMOs have announced 2025–2027 expansion plans: WuXi AppTec 40,000L → 60,000L, Sinomartek 2,000 → 5,000 kg/yr
- CDMO→Innovative drug extension: Traditional CDMOs like Sainuo Biotech and Sinomartek are building proprietary innovative drug pipelines
- International certification barriers: FDA/EU GMP certification is becoming a core competitive differentiator for CDMO exports, with multi-certification companies commanding significant premiums
🏭 China Peptide CDMO Cluster Distribution
| Regional Cluster |
Core Cities |
Representative Companies |
Capacity Characteristics |
Strategic Positioning |
| Yangtze River Delta |
Suzhou/Changzhou/Shanghai |
WuXi AppTec, Asymchem, Sinomartek (partial) |
Full-chain capabilities, export-oriented |
One-stop CDMO service platform |
| North China |
Beijing/Tianjin/Hebei |
Jiuzhou Pharma (Beijing), Hybio (partial) |
Northern market coverage |
Generic API + export |
| Pearl River Delta |
Shenzhen/Guangzhou |
Innovent (partial), Sainuo Biotech |
Innovative drugs + Biotech |
Drug R&D innovation |
| Central/Sichuan |
Chengdu |
Sainuo Biotech (Chengdu), Aurisco |
Low operating costs |
High-value CDMO services |
| West/Zhangjiakou |
Zhangjiakou |
SENO Biotechnology |
Differentiated CDMO capabilities |
Custom synthesis + purification |
| Shandong/Fujian |
Dispersed |
Small to medium production lines |
Generic API export focus |
Traditional API suppliers |
📊 Key Corporate Investment Metrics
| Metric |
Industry Average |
Best-in-Class |
What It Measures |
| CDMO Capacity Utilization |
75–85% |
>90% |
Capacity value realization |
| API Sales Gross Margin |
40–55% |
>60% |
Cost control + pricing power |
| International Client Revenue Share |
30–50% |
>60% |
Globalization capability |
| Technology Platform Revenue Share |
15–25% |
>30% |
Technology value-add |
| GMP Certifications Count |
1–2 |
>3 |
Quality control & international recognition |
| R&D Expense Ratio |
5–8% |
>10% |
Innovation pipeline & value |
| Client Concentration (Top 3) |
40–60% |
<30% |
Client diversification risk |
| Capacity Expansion Plan (3-yr) |
30–50% increase |
>80% increase |
Demand outlook assessment |
| Employees (R&D share) |
200–500 (25–35%) |
>500 (>40%) |
Team scale & R&D capability |
📈 Global Peptide Industry Funding Dynamics (2023–2025)
| Year |
Global Total Funding |
China Total Funding |
Largest Single Deal |
Hot Sectors |
| 2023 |
~$2.2B |
~¥4.5B |
Bicycle Therapeutics $555M Follow-on |
GLP-1 pipelines, oral delivery |
| 2024 |
~$3.5B |
~¥7.5B |
Eccogene Series B $200M |
GLP-1 generics, CDMO expansion |
| 2025 H1 |
~$2.0B |
~¥4.0B |
Multiple GLP-1 generic API companies |
Oral GLP-1, PDC drugs |
💡 Industry Supply Chain Key Data
| Supply Chain Segment |
China Share |
Other Countries Share |
Risk Level |
Notes |
| Protected Amino Acid Production |
55–60% |
Japan/Switzerland 30–35% |
🟡 Medium |
High import dependence on unnatural AAs |
| Peptide API Synthesis |
35–40% |
Switzerland 20–25% |
🔴 High |
Capacity utilization >90% |
| Purification Resins/Consumables |
20–25% |
US/Japan 60–65% |
🔴 High |
High-end chromatographic media import-dependent |
| Analytical Instruments/QC |
15–20% |
US/Germany 70–75% |
🔴 High |
High-end MS/chromatography imports |
| CDMO Services |
32% |
Switzerland/EU/US 50%+ |
🟡 Medium |
Rapidly catching up |
| Finished Drug Product |
25–30% |
EU/US 55–60% |
🟢 Low |
Accelerating localization trend |
Supply Chain Risk Alert
The global peptide API supply chain exhibits a "China + Switzerland" bipolar格局, with China providing bulk capacity (cost advantage) and Switzerland offering high-end custom synthesis with EU/US GMP certification. GLP-1 API demand is projected to grow from 12,000 kg/yr to 25,000–35,000 kg/yr in 2025–2027, continuing supply chain tightness. Geopolitical risks (US-China trade tariffs, EU DMF/NMP environmental limits) add supply chain uncertainty, making diversified sourcing strategies essential.
🧭 Navigation Guide
🏢 Corporate Collaboration & Investment Advisory: This platform's corporate analysis is compiled from public financial reports, industry announcements, and analyst reports. Data is current as of the latest earnings release; some figures are estimates. For due diligence, competitive benchmarking, or CDMO partner evaluation on specific companies, contact SENO Biotechnology for peptide CDMO and industry analysis services → Learn more at senopeptide.com/about/